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Abstract: Transcranial focal stimulation (TFS) is a non-invasive neuromodulation strategy with
neuroprotective effects. On the other hand, 6-hidroxidopamine (6-OHDA) induces neurodegenera-
tion of the nigrostriatal system producing modifications in the dopaminergic, serotoninergic, and
histaminergic systems. The present study was conducted to test whether repetitive application of
TFS avoids the biogenic amines´ changes induced by the intrastriatal injection of 6-OHDA. Experi-
ments were designed to determine the tissue content of dopamine, serotonin, and histamine in the
brain of animals injected with 6-OHDA and then receiving daily TFS for 21 days. Tissue content of
biogenic amines was evaluated in the cerebral cortex, hippocampus, amygdala, and striatum, ipsi-
and contralateral to the side of 6-OHDA injection. Results obtained were compared to animals with
6-OHDA, TFS alone, and a Sham group. The present study revealed that TFS did not avoid the
changes in the tissue content of dopamine in striatum. However, TFS was able to avoid several of
the changes induced by 6-OHDA in the tissue content of dopamine, serotonin, and histamine in the
different brain areas evaluated. Interestingly, TFS alone did not induce significant changes in the
different brain areas evaluated. The present study showed that repetitive TFS avoids the biogenic
amines´ changes induced by 6-OHDA. TFS can represent a new therapeutic strategy to avoid the
neurotoxicity induced by 6-OHDA.
Keywords: non-invasive neuromodulation; 6-hidroxidopamine; dopamine; serotonin; histamine;
transcranial focal stimulation
1. Introduction
The electrical modulation of the brain induced by strategies such as deep brain
stimulation and vagal nerve stimulation has been considered an alternative treatment
to control neurological disorders such as Parkinson´s disease and pharmacoresistant
epilepsy [1–3]. However, these strategies of neuromodulation are invasive and have high
economical costs [4,5].
On the one hand, transcranial focal stimulation (TFS) applied via tripolar concen-
tric ring electrodes (TCREs) is a non-invasive strategy of neuromodulation that induces
inhibitory and neuroprotective effects. TFS decreases the expression of the convulsive
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activity produced by pilocarpine, penicillin, and pentylenetetrazole [6–9]. TFS combined
with sub-effective doses of diazepam reduces the incidence of mild and severe general-
ized pilocarpine-induced seizures, an effect associated with lower neuronal damage [10].
We recently found that TFS avoids the P-glycoprotein overexpression induced after an
acute convulsive seizure and enhances the phenytoin effects in an experimental model of
drug-resistant seizures [11]. The neuroprotective effects of TFS have been associated with
lessened evoked glutamate release in vivo [12].
On the other hand, 6-hydroxydopamine (6-OHDA) is a toxin used to induce selec-
tive damage of catecholaminergic neurons and neurodegeneration of the nigrostriatal
system [13]. The neurotoxicity induced by 6-OHDA is explained by the oxidative stress
that results from the generation of reactive oxygen species (ROS) as a consequence of its
auto-oxidation [14]. This condition associated with augmented free calcium can lead to cell
death [15]. 6-OHDA is widely used to reproduce some of Parkinson’s disease signs as a
result of neuroinflammation, neurodegeneration, apoptosis [16], and loss of dopaminergic
neurons in the brain area injected [17].
In addition to the disruption of dopaminergic neurotransmission, 6-OHDA also mod-
ifies the neurotransmission mediated by other biogenic amines. The bilateral medial
forebrain bundle 6-OHDA injection reduces serotonin tissue levels in the striatum [18].
6-OHDA significantly augments histamine content in different brain areas (hypothalamus,
hippocampus, and medulla oblongata) [19], a condition that facilitates neurodegeneration
induced by the toxin [20].
It is described that neuromodulation strategies modify the neurotransmission medi-
ated by histamine [21], serotonin, and dopamine [22]. The present study was designed
to support the hypothesis that repetitive application of TFS can reduce the neurotoxic
effects induced by 6-OHDA. Experiments were designed to evaluate the tissue content
of dopamine, serotonin, and histamine in different brain areas of animals treated with an
intrastriatal injection of 6-OHDA and subsequent repetitive application of TFS.
2. Results
2.1. TFS Did Not Alter the Tissue Content of Biogenic Amines
The Sham group showed the following tissue content values of biogenic amines
expressed in µM/mg of protein, ipsi- and contralateral to the place of vehicle injection: a)
dopamine: striatum, 186 ± 18 and 229 ± 20, respectively; cortex, 11.6 ± 1.8 and 24.2 ± 4.3;
hippocampus, 12.5 ± 1 and 15 ± 1.7, respectively; amygdala, 13.9 ± 2.3 and 18.3 ± 1.2,
respectively; b) serotonin: striatum, 57 ± 3 and 62.9 ± 6.2, respectively; cortex, 57.9 ± 7.5
and 68.6 ± 9; hippocampus, 56.6 ± 13 and 70.1 ± 6.1, respectively; amygdala, 157.4 ± 23 and
174 ± 10, respectively; c) histamine: striatum, 14.4 ± 1.6 and 13.6 ± 1.2, respectively; cortex,
11.8 ± 0.7 and 14.2 ± 1.6; hippocampus, 14 ± 1.1 and 14.2 ± 1.7, respectively; amygdala,
12.7 ± 0.7 and 14.3 ± 1.4, respectively. TFS did not induce behavioral changes during its
repetitive application to the TFS group. The tissue content of dopamine, serotonin, and
histamine in the different brain areas of the TFS group was similar to the Sham group
(Figures 1–3). These results suggest that TFS does not modify the normal brain function.
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Figure 1. Effects of TFS on the changes in dopamine tissue content induced by 6-OHDA in different brain areas. Tissue 
content ipsi- and contralateral to the toxin injection or vehicle is expressed as µM/mg of protein. Sham, animals with 
vehicle injection; TFS, animals receiving TFS daily for 21 days; 6OH, rats injected with 6-OHDA; 6-OH-TFS, animals re-
ceiving repetitive TFS after 6-OHDA injection. Data are expressed as mean ± standard error. * p < 0.05 vs Sham group; ** 
p < 0.01 vs Sham group; *** p < 0.001 vs Sham group; @ p < 0.05 vs 6-OHDA group; @@ p < 0.01 vs 6-OHDA group. The results 
obtained were analyzed with ANOVA followed by the post hoc Tukey test. 
Figure 1. Effects of TFS on the changes in dopamine tissue content induced by 6-OHDA in different brain areas. Tissue
content ipsi- and contralateral to the toxin injection or vehicle is expressed as µM/mg of protein. Sham, animals with vehicle
injection; TFS, animals receiving TFS daily for 21 days; 6OH, rats injected with 6-OHDA; 6-OH-TFS, animals receiving
repetitive TFS after 6-OHDA injection. Data are expressed as mean ± standard error. * p < 0.05 vs Sham group; ** p < 0.01 vs
Sham group; *** p < 0.001 vs Sham group; @ p < 0.05 vs 6-OHDA group; @@ p < 0.01 vs 6-OHDA group. The results obtained
were analyzed with ANOVA followed by the post hoc Tukey test.
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Figure 2. Effects of TFS on the changes in serotonin tissue content induced by 6-OHDA in different brain areas. Notations 
as in Figure 1. * p < 0.05 vs Sham group; ** p < 0.01 vs Sham group; *** p < 0.001 vs Sham group; **** p < 0.0001 vs Sham 
group; @ p < 0.05 vs 6-OHDA group; @@ p < 0.01 vs 6-OHDA group. The results obtained were analyzed with ANOVA 
followed by the post hoc Tukey test. 
Figure 2. Effects of TFS on the changes in serotonin tissue content induced by 6-OHDA in different brain areas. Notations
as in Figure 1. * p < 0.05 vs Sham group; ** p < 0.01 vs Sham group; *** p < 0.001 vs Sham group; **** p < 0.0001 vs Sham
group; @ p < 0.05 vs 6-OHDA group; @@ p < 0.01 vs 6-OHDA group. The results obtained were analyzed with ANOVA
followed by the post hoc Tukey test.
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Figure 3. Effects of TFS on the changes of histamine tissue content induced by 6-OHDA in different brain areas. Notations 
as in Figure 1. * p < 0.05 vs Sham group; ** p < 0.01 vs Sham group; *** p < 0.001 vs Sham group; **** p < 0.0001 vs Sham 
group; @ p < 0.05 vs 6-OHDA group; @@ p < 0.01 vs 6-OHDA group; @@@ p < 0.001 vs 6-OHDA group. The results obtained 
were analyzed with ANOVA followed by the post hoc Tukey test. 
Figure 3. Effects of TFS on the changes of histamine tissue content induced by 6-OHDA in different brain areas. Notations
as in Figure 1. * p < 0.05 vs Sham group; ** p < 0.01 vs Sham group; *** p < 0.001 vs Sham group; **** p < 0.0001 vs Sham
group; @ p < 0.05 vs 6-OHDA group; @@ p < 0.01 vs 6-OHDA group; @@@ p < 0.001 vs 6-OHDA group. The results obtained
were analyzed with ANOVA followed by the post hoc Tukey test.
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2.2. Intrastriatal Administration of 6-OHDA Modifies the Brain Tissue Content of
Biogenic Amines
In contrast to the Sham group, animals from the 6-OHDA group showed a lower tissue
content of dopamine in all the brain areas evaluated. This effect was more evident in the
striatum, ipsi- and contralateral to the 6-OHDA administration (96% and 97%, respectively,
p < 0.0001 vs Sham group) (Figure 1). Similarly, the tissue content of serotonin was lower
in all cerebral structures analyzed (Figure 2). Concerning histamine and when compared
with the Sham group, the 6-OHDA group presented high tissue content in ipsilateral
striatum (80%, p < 0.0001), cortex (76%, p < 0.0006), and hippocampus (48%, p < 0.01); as
well as bilateral amygdalae (ipsi- 82%, p < 0.0009; contra- 60%, p < 0.01). The experiments
also revealed low histamine tissue content in the contralateral striatum (45%, p < 0.006)
(Figure 3). According to the results obtained, 6-OHDA induces significant changes in the
tissue content of biogenic amines in different brain areas, ipsi- and contralateral to a lesion.
2.3. TFS Modifies the Changes in the Tissue Content of Biogenic Amines Induced by the
Intrastriatal Administration of 6-OHDA
Animals from the 6-OHDA-TFS group showed similarly low levels of dopamine tissue
content in the striatum, ipsi- and contralateral to the side of toxin injection, when compared
with the 6-OHDA group. However, the results obtained revealed that the other brain areas
evaluated presented tissue content of dopamine similar to the Sham group. Indeed, the
hippocampus and amygdala showed a significantly high tissue content of dopamine when
compared with the 6-OHDA group (Figure 1).
The 6-OHDA-TFS group showed low serotonin tissue content in all the brain areas
evaluated. However, when compared with the 6-OHDA group, higher values were de-
tected in ipsi- and contralateral striatum (p < 0.02 and p < 0.05, respectively), as well as
contralateral cortex (p < 0.001) and hippocampus (p < 0.001) (Figure 2).
Concerning histamine tissue content, animals from the 6-OHDA-TFS group presented
values similar to the Sham group. When compared with the 6-OHDA group, lower
values were detected in ipsilateral cortex, hippocampus, and amygdala (p < 0.03, p < 0.05,
and p < 0.004, respectively) and contralateral amygdala (p < 0.02) (Figure 3).
The results obtained from the 6-OHDA-TFS group indicate that TFS applied daily
for 2 h per day for 21 days does not avoid the loss of dopamine in the lesioned striatum.
However, it protected peripheral structures from changes in biogenic amines induced by
the toxin.
3. Discussion
The present study results indicate that the repetitive application of TFS for 21 days in
normal animals did not modify the tissue content of dopamine, serotonin, and histamine
in the different brain areas evaluated. However, repetitive TFS application avoids some of
the long-term changes induced by the intrastriatal injection of 6-OHDA in biogenic amines
in the striatum, cortex, hippocampus, and amygdala.
It is known that the dopamine and serotonin tissue levels in the striatum and other
brain areas such as the cerebral cortex and the hippocampus, decrease as a consequence
of 6-OHDA intrastriatal injection [23–25]. 6-OHDA selectively destroys dopaminergic
neurons due to its high affinity to the dopamine transporter [26,27]. 6-OHDA can also
destroy adjacent cells as a result of the formation of ROS [16,27]. This situation explains
the simultaneous changes in dopamine and serotonin in different brain areas induced by
6-OHDA. In contrast, we found that 6-OHDA induces enhanced tissue levels of histamine
in different brain areas. This effect is similar to the results previously reported by other
authors in rats [19,28] and patients with Parkinson’s Disease [29,30]. The high tissue
content of histamine may contribute to the neuroinflammation process produced by the
toxin administration [31].
Our results reveal that the repetitive application of TFS for 21 days avoided some
of the changes of the biogenic amines tissue content induced by the striatal injection of
Pharmaceuticals 2021, 14, 706 7 of 11
6-OHDA. These protective effects are similar to those induced by other strategies of neuro-
modulation. Deep brain stimulation improves the survival of dopaminergic neurons and
avoids alterations in the tissue content of dopamine and serotonin in patients with Parkin-
son’s Disease [22]. Likewise, direct current stimulation applied for 4 weeks prevents the
depletion of dopaminergic neurons induced by 6-OHDA, improving the motor alterations
in the animals [32].
In the present study, animals receiving 6-OHDA and TFS showed a higher tissue
content of dopamine in the different evaluated brain areas, when compared with the 6-
OHDA group. Similarly, neuromodulation strategies such as high-frequency stimulation
in 6-OHDA lesioned rats augment the extracellular levels of dopamine in the striatum [33].
It is known that behavioral and mood alterations in patients with Parkinson´s Disease
are associated with reduced plasma levels of serotonin, suggesting its low neurotransmis-
sion [34]. Studies indicate that deep brain stimulation decreases serotoninergic neurotrans-
mission [35–37]. Electrical stimulation of the subthalamic nucleus, a strategy used to reduce
motor dysfunction in Parkinson´s disease patients, results in more evident behavioral and
mood alterations [38,39]. This evidence supports that deep brain stimulation exacerbates
the reduced serotoninergic neurotransmission associated with Parkinson´s Disease. In
the present study, we found that rats from the 6-OHDA-TFS group showed higher tissue
content of serotonin in contrast with the 6-OHDA group. Our results support that TFS is
more effective than deep brain stimulation to avoid serotonin changes induced by 6-OHDA.
Studies indicate that high histamine levels in arkinsonian basal ganglia circuitry
represent a compensatory mechanism for regulating the firing patterns of subthalamic
neurons and decreasing motor dysfunction [40]. Nevertheless, the increased levels of
histamine in other brain areas could lead to neuroinflammation with a consequent neuronal
degeneration found in neurological disorders such as Parkinson´s disease [31]. Indeed, it is
known that 90% of the histamine in brain areas such as the hippocampus is released from
mast cells [41] that participate in neuroinflammation and cell damage [42,43]. In the present
study, we found that TFS avoids the increased levels of histamine-induced by 6-OHDA in
the ipsilateral striatum, cortex, and hippocampus and bilateral amygdalae. These results
suggest that TFS represents a neuroprotective strategy in the 6-OHDA lesioned rats.
It is also important to mention that the repetitive application of TFS in normal animals
did not produce changes in the brain tissue content of the biogenic amines evaluated. In
contrast, the repetitive application of transcranial magnetic stimulation increases the striatal
dopamine levels in control rats [44]. This group of evidence supports that TFS represents a
good neuromodulatory strategy to avoid the toxic effects of 6-OHDA in the brain.
The unilateral application of 6-OHDA induces cell death and oxidative stress [45],
both of these phenomena could be associated with changes in the biogenic amines. The
present study presents important limitations for possible clinical implications of the TFS.
One limitation is the lack of behavioral and histological evaluation. Future studies should
be carried out to test whether TFS can avoid the behavioral and cellular changes induced
by 6-OHDA. Another important limitation is that there was a limited number of animals
used for each experimental group. Although this situation restricts the significance of the
data obtained, the effects of TFS on the tissue levels of biogenic amines are evident.
4. Materials and Methods
4.1. Animals
Adult male Wistar rats, initially weighing 250–300 g, were individually housed at
22 ◦C and maintained on a 12-h light/dark cycle. Animals had free access to food and
water. According to the Mexican Official Standard (NOM-062-ZOO-1999) and the Ethical
Committee of the Center for Research and Advanced Studies (Protocol #175/15 with
approval date of 04/05/2016), the present study was carried out.
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4.2. Surgery and Intrastriatal Injection of 6-OHDA
Rats were anesthetized with a mixture of ketamine (80 mg/kg, i.p.) and xylazine
(20 mg/kg, i.m.). Through a trepan in the skull, an intrastriatal injection of 6-OHDA was
applied (4 µg/µL in ascorbic acid 0.01%, 0.9% de NaCl, total 4 µL). The toxin was injected
slowly (0.5 µL /min) into the right striatum (AP, +0.7 mm from Bregma; lateral 3.8 mm;
ventral from the dura 5.0 mm). Then, a 6 mm diameter TCRE attached to male connector
pins was placed centered on the cranium, 5 mm behind Bregma. Four stainless steel screws
were threaded into the cranium over the frontal and cerebellar cortices and the electrode
assembly was affixed to the skull with dental acrylic. Animals were allowed to recover for
2 days before any further manipulation.
4.3. Experimental Groups
6-OHDA-TFS group (n = 6). Two days after implanting and injection with 6-OHDA,
animals received TFS daily for 2 h per day for 21 days. TFS consisted of 200 µs symmetrical
biphasic square charge-balanced constant current pulses at a rate of 300 Hz and an intensity
of 100 µA. TFS was applied through the outer ring (external diameter of 6.0 mm) and
the disc of a TCRE (with the middle ring floating). For this purpose, we used two Grass
Technologies S48 square pulse stimulators each with an SIU-C constant current stimulus
isolation unit (Grass Technologies, West Warwick, RI). One S48 provided the positive pulses
and the other provided the negative pulses. The day after the last TFS, rats were killed by
decapitation, and the brain was obtained. Striatum, cortex, amygdala, and hippocampus,
ipsi- and contralateral to the place of 6-OHDA injection, were dissected and immediately
stored in polypropylene Eppendorf tubes at -70 ◦C.
6-OHDA group (n = 6). Rats were manipulated as indicated previously for the 6-
OHDA-TFS group, except that they did not receive TFS.
TFS group (n = 6). Rats were manipulated as indicated previously for the 6-OHDA-
TFS group, except that they received an intrastriatal injection of the vehicle instead of
6-OHDA.
Sham group (n = 6). Rats were manipulated as indicated previously for the 6-OHDA
group, except that they received an intrastriatal injection of the vehicle instead of toxin.
4.4. Evaluation of Tissue Content of Biogenic Amines by Chromatography
Brain tissue samples (10–100 mg each) were homogenized on ice in 90 µL HClO4 0.1 M
using a tissue homogenizer. The homogenate was centrifuged at 13,000 rpm for 15 min
at 4 ◦C and the resulting supernatant was filtrated by a Nalgene-nylon 0.45 µm filter and
stored at −70 ◦C until use.
Then, 20 µL of the stored sample was injected into the solvent stream of a high-
performance liquid chromatography system. Dopamine and serotonin levels were eluted
using a reversed-phase column (C18, 3 µm; 2.1 × 50 mm; Atlantis, Waters®, Milford, MA,
USA) coupled to a pre-column (Atlantis, Waters®, Milford, MA, USA) and mobile phase
solution containing sodium acetate 25 mM, EDTA 0.01 mM; citric acid 25 mM and 1-octane
sulfonic acid 1 mM dissolved in milli-Q water and mixed with acetonitrile in a proportion
of 95:5, pH 3.35 ± 0.05 at a flow rate of 0.35 mL/min. Dopamine and serotonin detection
was performed by a single-channel electrochemical detector (Waters® model 2465, Milford,
MA, USA) at 450 mV at 30 ◦C.
For histamine levels, 15 µL of the sample was mixed with 10 µL OPA-NAC solution
pH 9.3 ± 0.05 [46] in a vial. It was eluted using a reversed-phase column (C18, 4 µm;
3.9 × 150 mm; Nova-Pak, Waters®, Milford, MA, USA). A Ternary elution system was
employed in a gradient flow with aqueous acetate phosphate buffer pH 5.05 ± 0.05 (eluent
A), HPLC grade acetonitrile (eluent B), and milli-Q water (eluent C) [47]. The detection
of histamine was performed by fluorescence detector (Waters® model 474, Milford, MA,
USA) with an excitation wavelength of 360 nm, an emission wavelength of 450 nm, and a
gain value of 100. Peak height measurements quantified all the biogenic amines against
standard solutions.
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The pellet obtained from the homogenization of each brain sample was resuspended
in fresh NaOH 0.1 N, and protein levels were determined by the method of Bradford [48].
The obtained values allowed expressing the data resulting from the high-performance
liquid chromatography in µM/mg of proteins.
4.5. Statistical Analysis and Sample Size
Previous studies indicate that six animals per group is the minimum sample size
to detect significant differences in pilot studies evaluating quantitative variables [49].
According to this notion, the sample size for the present study was six rats per group.
Values were expressed as mean ± S.E.M. The results obtained were analyzed with
ANOVA followed by the post hoc Tukey test. In all statistical comparisons, p < 0.05 was
used as the criterion for significance.
5. Conclusions
TFS is a non-invasive neuromodulatory strategy with neuroprotective effects that also
avoids most of the neurochemical abnormalities caused by the intrastriatal injection of
6-OHDA in the dopaminergic, serotoninergic, and histaminergic systems. Further research
is needed to determine if TFS is able to protect the animals from the motor dysfunction
and cell damage induced by the toxin.
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